Presentation is loading. Please wait.

Presentation is loading. Please wait.

Changes in autoantibody titers and GADA IgG1–4 subclass distribution.

Published byΑθανας Λιάπης Modified over 5 years ago

Similar presentations

Presentation on theme: "Changes in autoantibody titers and GADA IgG1–4 subclass distribution."— Presentation transcript:

1 Changes in autoantibody titers and GADA IgG1–4 subclass distribution.
Changes in autoantibody titers and GADA IgG1–4 subclass distribution. GADA median titers (A), GADA median fold-change from baseline (B), and IA-2A median titers (C) in 4D (n = 49, black circles), 2D (n = 49, gray circles), and placebo (n = 50, empty circles). The median GADA IgG subclass distribution is presented as a percentage of total IgG for 4D (D), 2D (E), and placebo (F). Results were expressed as cpm, and positivity of each sample was calculated by subtraction of the mean cpm value plus three times the SD obtained for the negative control. Significant differences are indicated as P values. M, months. Stina Axelsson et al. Dia Care 2013;36: ©2013 by American Diabetes Association

Download ppt "Changes in autoantibody titers and GADA IgG1–4 subclass distribution."

Similar presentations

A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.

A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Breadth of binding and HAI activity of serum Ab from i. n. + i. p

Breadth of binding and HAI activity of serum Ab from i. n. + i. p
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Serum IgG subclass representation from BALB/c mice (n = 5/group) following COBRA P1 virus i.n., i.p., or i.m. prime followed by i.p. or i.m. boost. Serum.

Serum IgG subclass representation from BALB/c mice (n = 5/group) following COBRA P1 virus i.n., i.p., or i.m. prime followed by i.p. or i.m. boost. Serum.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.
(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.
Figure 1 Total IgG, IgA, and IgM levels and hypo-Ig prevalence during RTX treatment Total IgG, IgA, and IgM levels and hypo-Ig prevalence during RTX treatment.

Figure 1 Total IgG, IgA, and IgM levels and hypo-Ig prevalence during RTX treatment Total IgG, IgA, and IgM levels and hypo-Ig prevalence during RTX treatment.
Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs7903146 polymorphism and the dietary intervention group after.

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.
Group differences (DKA vs

Group differences (DKA vs
Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.

Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.
The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.
Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.
Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),
(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.

(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.
Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.

Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.
Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

Similar presentations

Ads by Google